Bone Targeted Therapy with Zoledronate or Denosumab is Required in Men with mCRPC Responding to Anticancer Therapy - Noel Clarke

April 19, 2017

Noel Clarke a Consultant Urologist at Salford Royal Hospital presents in opposition of treating all patients with bone-targeted therapy during his portion of the debate on bone-targeted therapy with zoledronate or denosumab.

Access to all Advanced Prostate Cancer Consensus Conference Video Coverage

Read the 2017 APCCC Report on Management of Patients with Advanced Prostate Cancer